MedPacto Obtains Domestic Patent for Bactosertib Manufacturing... "Simplifying Synthesis and Production Steps"

MedPacto announced on the 9th that it has obtained a domestic patent related to the manufacturing of 'Bactosertib,' an anticancer drug under development.

The newly acquired patent is titled "Intermediate useful for the synthesis of TGF-β inhibitors and a method for manufacturing TGF-β inhibitors using the same." This patent covers a manufacturing method suitable for the mass production of Bactosertib. According to MedPacto, unlike existing methods, it is cost-effective, simplifies the synthesis steps and purification process, and improves reaction yield.

The company stated that the manufacturing method under this patent allows the use of inexpensive and safe reagents and simplifies the purification process to increase reaction yield. They also added that the patent can be utilized to enhance production efficiency and be useful for mass production.

MedPacto plans to apply this patent in the production according to the development stages of Bactosertib in the future.

A MedPacto representative said, "We have developed a synthesis method for Bactosertib that has shorter reaction steps and higher reaction yield compared to existing methods," adding, "We expect that applying this method at the commercialization stage of Bactosertib will reduce raw material costs."

MedPacto is preparing for a global Phase 3 clinical trial of Bactosertib in combination therapy with the immuno-oncology drug 'Keytruda' for colorectal cancer.

This content was produced with the assistance of AI translation services.